7 to 7,000 Employees in 9 Months

20VC with Harry Stebbings · 0m · transcribed 1d ago

Section Insights

# 0:00

The Emergence of COVID Testing

How did the company respond to the initial COVID testing crisis?

In response to the COVID-19 pandemic and the lack of testing availability, the chief scientific officer developed a COVID test, leading to a peak of 206,000 tests conducted in a single day.

The urgency of the pandemic prompted rapid innovation in testing.
The company played a critical role in addressing the testing shortage during lockdowns.

# 0:11

Introduction to Fred Turner and Curative

Who is Fred Turner and what did Curative achieve?

Fred Turner, co-founder and CEO of Curative, scaled a COVID testing business to $5 billion in revenue during the pandemic.

Curative experienced explosive growth due to the pandemic.
The company was founded by an English entrepreneur in Silicon Valley.

# 0:22

Post-COVID Transition

What happened to Curative after the peak of COVID testing?

After the peak, Curative had to scale back its operations as the demand for COVID testing decreased, eventually transforming into a health insurance provider valued at $1.3 billion.

The business model had to adapt significantly post-COVID.
Curative's transition highlights the challenges of sustaining pandemic-driven growth.

# 0:33

Rapid Growth and Challenges

What was the impact of the pandemic on Curative's workforce and services?

Curative's workforce grew from about 7 to 7,000 employees in just nine months, and they administered 2.5 million vaccinations, although this service was financially challenging.

The company faced immense operational scaling challenges.
Despite high vaccination numbers, the financial sustainability of the service was questionable.

# 0:44

Financial Struggles and Strategic Cuts

What financial challenges is Curative facing?

Curative is cutting about 80% of its SaaS spending due to significant financial losses, indicating struggles in maintaining profitability.

The company is making drastic cuts to manage financial health.
High operational costs during the pandemic have led to ongoing financial challenges.

Transcript

0:00 Lockdowns had just started. Everybody was starting to freak out. There was basically nowhere to get a test. So, our chief scientific officer had, in his spare time, developed a COVID test. I think our peak day was 206,000 people tested in a single day. >> I'm so excited for a freaking wild stories today. Fred Turner, co-founder and CEO of Curative. This is an English founder in the Valley who scaled a COVID testing business to $5 billion in revenue. Then, he had to scale it all back. It did not last post-COVID for obvious reasons. Today, he turned it into a health insurance provider that's worth $1.3 billion.

0:36 And in the show, he says some pretty wild stuff. >> And the company went from about 7 to 7,000 employees in those first 9 months. We did 2 and 1/2 million vaccinations. That was another service we did. We also lost a ton of money on that. That was a terrible business. We're cutting about 80% of our SaaS spend this year. >> What's the single largest contract you signed?

Summary

Fred Turner, co-founder and CEO of Curative, shares his journey of rapidly scaling a COVID testing business that reached $5 billion in revenue during the pandemic, only to face significant challenges as demand waned. He has since pivoted the company into a health insurance provider valued at $1.3 billion, reflecting on the wild ride of growth and subsequent contraction.

- Curative developed a COVID test during the early days of the pandemic when testing was scarce.
- The company peaked at 206,000 tests conducted in a single day.
- Employee count skyrocketed from 7 to 7,000 within nine months.
- Curative administered 2.5 million vaccinations, despite losing money on that service.
- The company is cutting 80% of its SaaS expenditures in response to changing market conditions.
- Turner discusses the challenges of scaling back operations post-COVID.
- Curative's transformation into a health insurance provider demonstrates adaptability in a shifting landscape.